Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

This study has been terminated.
(Closed per Data Monitoring Committee due to toxicity & incomplete treatment of patients resulting in poor data.)
Eli Lilly and Company
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Northwestern University Identifier:
First received: February 9, 2006
Last updated: August 11, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: March 2019
  Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)